[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619320":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Pierre BOYER, MD","CONTACT","33 3 69 55 14 69","pierre.boyer@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Laboratoire de Bactériologie - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,34,36],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":31,"role":11,"phone":32,"phoneExt":7,"email":33},"Émilie TALAGRAND-REBOUL, MD","33 3 69 55 14 57","Emilie.TALAGRANDREBOUL@chru-strasbourg.fr",{"name":10,"role":35,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":37,"role":35,"phone":7,"phoneExt":7,"email":7},"Émilie TALAGRAND-REBOUL",{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619320","a-multicenter-real-life-study-of-disseminated-borreliosis-cases-occurring-in-patients-receiving-anti-cd20-treatment-in-france-100619320",false,"NCT07343089","A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France","BorDiMab","Inclusion Criteria:\n\n* Minor or adult subject\n* Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study","ALL","1 Year",{"count":50,"type":51},100,"ESTIMATED","OBSERVATIONAL","Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.",[55],"Borrelia Infections",[57,55,58,59,60],"Borreliosis, Lyme","Borrelia Burgdorferi","Borrelia Miyamotoi","Anti-CD20 monoclonal antibodies","2026-01-06",{"date":63,"type":64},"2026-01-15","ACTUAL",{"date":66,"type":64},"2025-08-29",{"date":68,"type":51},"2026-08-29",{"name":5,"class":6},1]